Pericytes Modulate Third‐Generation Tyrosine Kinase Inhibitor Sensitivity in EGFR‐Mutated Lung Cancer Cells Through IL32‐β5‐Integrin Paracrine Signaling

Abstract EGFR‐mutated lung cancer patients sometimes display restricted responses to third‐generation tyrosine kinase inhibitors (TKIs), potentially attributable to undervalued input from stromal cells, notably pericytes (PCs). The study shows that PCs isolated from EGFR‐mutated patients have a uniq...

Full description

Saved in:
Bibliographic Details
Main Authors: Cheng Huang, Xi Huang, Xiaoyi Qiu, Xiangzhan Kong, Chunmiao Wu, Xue Jiang, Mingkang Yao, Minghui Wang, Liangping Su, Cui Lv, Ping‐Pui Wong
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Advanced Science
Subjects:
Online Access:https://doi.org/10.1002/advs.202405130
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850247199453085696
author Cheng Huang
Xi Huang
Xiaoyi Qiu
Xiangzhan Kong
Chunmiao Wu
Xue Jiang
Mingkang Yao
Minghui Wang
Liangping Su
Cui Lv
Ping‐Pui Wong
author_facet Cheng Huang
Xi Huang
Xiaoyi Qiu
Xiangzhan Kong
Chunmiao Wu
Xue Jiang
Mingkang Yao
Minghui Wang
Liangping Su
Cui Lv
Ping‐Pui Wong
author_sort Cheng Huang
collection DOAJ
description Abstract EGFR‐mutated lung cancer patients sometimes display restricted responses to third‐generation tyrosine kinase inhibitors (TKIs), potentially attributable to undervalued input from stromal cells, notably pericytes (PCs). The study shows that PCs isolated from EGFR‐mutated patients have a unique secretome profile, notably secreting IL32 and affecting signaling pathways and biological processes linked to TKI sensitivity. Clinical evidence, supported by single‐cell RNA sequencing and multiplex immunostaining of tumor tissues, confirms the presence of IL32‐expressing pericytes closely interacting with β5‐integrin‐expressing cancer cells in EGFR‐mutated patients, impacting therapeutic response and prognosis. Co‐culture and conditioned medium experiments demonstrate that PCs reduce TKI effectiveness in EGFR‐mutated cancer cells, a reversible phenomenon through silencing IL32 expression in PCs or depleting the IL32 receptor β5‐integrin on cancer cells, thereby restoring cancer cell sensitivity. Mechanistically, it is shown that YY1 signaling upregulates IL32 secretion in PCs, subsequently activating the β5‐integrin‐Src‐Akt pathway in EGFR‐mutated cancer cells, contributing to their TKI sensitivity. In animal studies, co‐injection of cancer cells with PCs compromises TKI effectiveness, independently of blood vessel functions, while inhibition of β5‐integrin restores tumor cell sensitivity. Overall, the findings highlight direct crosstalk between cancer cells and pericytes, impacting TKI sensitivity via IL32‐β5‐integrin paracrine signaling, proposing an enhanced therapeutic approach for EGFR‐mutated patients.
format Article
id doaj-art-124624bfeca340da8bf40159faa1c269
institution OA Journals
issn 2198-3844
language English
publishDate 2024-12-01
publisher Wiley
record_format Article
series Advanced Science
spelling doaj-art-124624bfeca340da8bf40159faa1c2692025-08-20T01:59:00ZengWileyAdvanced Science2198-38442024-12-011146n/an/a10.1002/advs.202405130Pericytes Modulate Third‐Generation Tyrosine Kinase Inhibitor Sensitivity in EGFR‐Mutated Lung Cancer Cells Through IL32‐β5‐Integrin Paracrine SignalingCheng Huang0Xi Huang1Xiaoyi Qiu2Xiangzhan Kong3Chunmiao Wu4Xue Jiang5Mingkang Yao6Minghui Wang7Liangping Su8Cui Lv9Ping‐Pui Wong10Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Guangdong‐Hong Kong Joint Laboratory for RNA Medicine Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou 510120 ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Guangdong‐Hong Kong Joint Laboratory for RNA Medicine Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou 510120 ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Guangdong‐Hong Kong Joint Laboratory for RNA Medicine Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou 510120 ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Guangdong‐Hong Kong Joint Laboratory for RNA Medicine Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou 510120 ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Guangdong‐Hong Kong Joint Laboratory for RNA Medicine Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou 510120 ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Guangdong‐Hong Kong Joint Laboratory for RNA Medicine Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou 510120 ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Guangdong‐Hong Kong Joint Laboratory for RNA Medicine Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou 510120 ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Guangdong‐Hong Kong Joint Laboratory for RNA Medicine Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou 510120 ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Guangdong‐Hong Kong Joint Laboratory for RNA Medicine Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou 510120 ChinaClinical Biobank Center Zhujiang Hospital Southern Medical University Guangzhou 510280 ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Guangdong‐Hong Kong Joint Laboratory for RNA Medicine Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou 510120 ChinaAbstract EGFR‐mutated lung cancer patients sometimes display restricted responses to third‐generation tyrosine kinase inhibitors (TKIs), potentially attributable to undervalued input from stromal cells, notably pericytes (PCs). The study shows that PCs isolated from EGFR‐mutated patients have a unique secretome profile, notably secreting IL32 and affecting signaling pathways and biological processes linked to TKI sensitivity. Clinical evidence, supported by single‐cell RNA sequencing and multiplex immunostaining of tumor tissues, confirms the presence of IL32‐expressing pericytes closely interacting with β5‐integrin‐expressing cancer cells in EGFR‐mutated patients, impacting therapeutic response and prognosis. Co‐culture and conditioned medium experiments demonstrate that PCs reduce TKI effectiveness in EGFR‐mutated cancer cells, a reversible phenomenon through silencing IL32 expression in PCs or depleting the IL32 receptor β5‐integrin on cancer cells, thereby restoring cancer cell sensitivity. Mechanistically, it is shown that YY1 signaling upregulates IL32 secretion in PCs, subsequently activating the β5‐integrin‐Src‐Akt pathway in EGFR‐mutated cancer cells, contributing to their TKI sensitivity. In animal studies, co‐injection of cancer cells with PCs compromises TKI effectiveness, independently of blood vessel functions, while inhibition of β5‐integrin restores tumor cell sensitivity. Overall, the findings highlight direct crosstalk between cancer cells and pericytes, impacting TKI sensitivity via IL32‐β5‐integrin paracrine signaling, proposing an enhanced therapeutic approach for EGFR‐mutated patients.https://doi.org/10.1002/advs.202405130β5‐integrinnon‐small cell lung cancerpericytestyrosine kinase inhibitor sensitivity
spellingShingle Cheng Huang
Xi Huang
Xiaoyi Qiu
Xiangzhan Kong
Chunmiao Wu
Xue Jiang
Mingkang Yao
Minghui Wang
Liangping Su
Cui Lv
Ping‐Pui Wong
Pericytes Modulate Third‐Generation Tyrosine Kinase Inhibitor Sensitivity in EGFR‐Mutated Lung Cancer Cells Through IL32‐β5‐Integrin Paracrine Signaling
Advanced Science
β5‐integrin
non‐small cell lung cancer
pericytes
tyrosine kinase inhibitor sensitivity
title Pericytes Modulate Third‐Generation Tyrosine Kinase Inhibitor Sensitivity in EGFR‐Mutated Lung Cancer Cells Through IL32‐β5‐Integrin Paracrine Signaling
title_full Pericytes Modulate Third‐Generation Tyrosine Kinase Inhibitor Sensitivity in EGFR‐Mutated Lung Cancer Cells Through IL32‐β5‐Integrin Paracrine Signaling
title_fullStr Pericytes Modulate Third‐Generation Tyrosine Kinase Inhibitor Sensitivity in EGFR‐Mutated Lung Cancer Cells Through IL32‐β5‐Integrin Paracrine Signaling
title_full_unstemmed Pericytes Modulate Third‐Generation Tyrosine Kinase Inhibitor Sensitivity in EGFR‐Mutated Lung Cancer Cells Through IL32‐β5‐Integrin Paracrine Signaling
title_short Pericytes Modulate Third‐Generation Tyrosine Kinase Inhibitor Sensitivity in EGFR‐Mutated Lung Cancer Cells Through IL32‐β5‐Integrin Paracrine Signaling
title_sort pericytes modulate third generation tyrosine kinase inhibitor sensitivity in egfr mutated lung cancer cells through il32 β5 integrin paracrine signaling
topic β5‐integrin
non‐small cell lung cancer
pericytes
tyrosine kinase inhibitor sensitivity
url https://doi.org/10.1002/advs.202405130
work_keys_str_mv AT chenghuang pericytesmodulatethirdgenerationtyrosinekinaseinhibitorsensitivityinegfrmutatedlungcancercellsthroughil32b5integrinparacrinesignaling
AT xihuang pericytesmodulatethirdgenerationtyrosinekinaseinhibitorsensitivityinegfrmutatedlungcancercellsthroughil32b5integrinparacrinesignaling
AT xiaoyiqiu pericytesmodulatethirdgenerationtyrosinekinaseinhibitorsensitivityinegfrmutatedlungcancercellsthroughil32b5integrinparacrinesignaling
AT xiangzhankong pericytesmodulatethirdgenerationtyrosinekinaseinhibitorsensitivityinegfrmutatedlungcancercellsthroughil32b5integrinparacrinesignaling
AT chunmiaowu pericytesmodulatethirdgenerationtyrosinekinaseinhibitorsensitivityinegfrmutatedlungcancercellsthroughil32b5integrinparacrinesignaling
AT xuejiang pericytesmodulatethirdgenerationtyrosinekinaseinhibitorsensitivityinegfrmutatedlungcancercellsthroughil32b5integrinparacrinesignaling
AT mingkangyao pericytesmodulatethirdgenerationtyrosinekinaseinhibitorsensitivityinegfrmutatedlungcancercellsthroughil32b5integrinparacrinesignaling
AT minghuiwang pericytesmodulatethirdgenerationtyrosinekinaseinhibitorsensitivityinegfrmutatedlungcancercellsthroughil32b5integrinparacrinesignaling
AT liangpingsu pericytesmodulatethirdgenerationtyrosinekinaseinhibitorsensitivityinegfrmutatedlungcancercellsthroughil32b5integrinparacrinesignaling
AT cuilv pericytesmodulatethirdgenerationtyrosinekinaseinhibitorsensitivityinegfrmutatedlungcancercellsthroughil32b5integrinparacrinesignaling
AT pingpuiwong pericytesmodulatethirdgenerationtyrosinekinaseinhibitorsensitivityinegfrmutatedlungcancercellsthroughil32b5integrinparacrinesignaling